Conference call interim report
Rhea-AI Summary
Vitrolife AB (VTRLY) has announced a conference call to present its Q1 2025 interim report scheduled for Thursday, April 24, 2025, at 10:00 AM CET. The presentation will be conducted in English.
Key participants from Vitrolife include CEO Bronwyn Brophy O'Connor and acting CFO Helena Wennerström. The interim report press release will be published at 8:00 AM CET on the same day, with presentation materials available on the company website before the call.
Interested parties must register to receive telephone numbers and access PINs for the conference. A recorded version will be accessible for seven days following the call at +44 (0) 20 3451 9993 using access code 8141544#.
Positive
- None.
Negative
- None.
Time: Thursday 24 April, 2025 at 10.00 a.m. CET.
To attend the conference call, please use this link to register. After registration, you will be provided with telephone numbers, conference PIN, and personal PIN to access the conference. Your personal data will be processed in accordance with our privacy policy available at: Privacy policy
Vitrolife Group participants:
Bronwyn Brophy O´Connor, CEO
Helena Wennerström, acting CFO
The press release for the interim report will be released at 8.00 CET on the same day.
Before the conference call, presentation material will be available at the company web page.
A recorded version of the telephone conference will be available for seven days on number +44 (0) 20 3451 9993 (International), access code 8141544#.
VITROLIFE AB (publ)
Contact:
Amelie Wilson, Investor Relations, awilson@vitrolife.com
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com.
https://news.cision.com/vitrolife-ab--publ-/r/conference-call-interim-report,c4133413
The following files are available for download:
Conference call interim report |
View original content:https://www.prnewswire.com/news-releases/conference-call-interim-report-302425490.html
SOURCE Vitrolife AB (publ)